Oral small molecules for the treatment of atopic dermatitis: a systematic review

Mobasher, Pezhman; Seradj, Mehran Heydari; Raffi, Jodie; Juhász, Margit; Mesinkovska, Natasha Atanaskova

doi:10.1080/09546634.2018.1544412

Cited by 11 publications

(14 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Depending on whether IL-13 binds to the type II receptor and/or to Signaling of IL-13 through IL-4Rα and IL-13Rα1 (type II) is linked to JAK1 and TYK2, respectively, and several JAK inhibitors (JAKis) with different JAK selectivity profiles are in development in a variety of conditions, including AD. 78 These first-generation JAKis are less selective and block predominantly JAK1 and JAK2 (ruxolitinib and baricitinib), JAK1 and TYK2 (PF-06700841), or all JAKs (delgocitinib, tofacitinib, peficitinib, and oclacitinib). 79 The second generation of JAKis of interest for blocking IL-13 activity displays a more selective inhibition of either JAK1 (abrocitinib, filgotinib, upadacitinib, and itacitinib) or TYK2 (BMS-986165).…”

Section: Kinase Inhibitorsmentioning

confidence: 99%

“…Signaling of IL‐13 through IL‐4Rα and IL‐13Rα1 (type II) is linked to JAK1 and TYK2, respectively, and several JAK inhibitors (JAKis) with different JAK selectivity profiles are in development in a variety of conditions, including AD . These first‐generation JAKis are less selective and block predominantly JAK1 and JAK2 (ruxolitinib and baricitinib), JAK1 and TYK2 (PF‐06700841), or all JAKs (delgocitinib, tofacitinib, peficitinib, and oclacitinib) …”

Section: Ppimsmentioning

confidence: 99%

See 1 more Smart Citation

Interleukin‐13: Targeting an underestimated cytokine in atopic dermatitis

Bieber¹

2019

Allergy

225

273

View full text Add to dashboard Cite

Atopic dermatitis (AD) is a common inflammatory skin condition that has traditionally been considered a paradigmatic type 2 immunity (T2)-driven disease. Interleukin (IL)-4 and IL-13 are both pivotal cytokines involved in the generation of allergic diseases. Currently, besides dupilumab, which blocks the binding of both cytokines to their receptors, a number of new pharmacologic entities have been designed to target both T2 cytokines and/or their receptors and/or receptor-associated signal transduction machinery such as Janus kinases. Recently, IL-13 has been suggested to be the key T2 cytokine driving inflammation in the periphery, while IL-4 may merely have a central effect. There is increasing evidence that this concept holds true for the inflammatory reaction underlying AD, where IL-13 is overexpressed locally and has a significant impact on skin biology, including the recruitment of inflammatory cells, the alteration of the skin microbiome, and the decrease in the epidermal barrier function. This review provides an update on the role of IL-13 in AD and discusses the different strategies aimed at interfering with its biologic activity as well as their potential in a precision medicine approach in the management of AD.

show abstract

Section: Kinase Inhibitorsmentioning

confidence: 99%

Section: Ppimsmentioning

confidence: 99%

Interleukin‐13: Targeting an underestimated cytokine in atopic dermatitis

Bieber¹

2019

Allergy

225

273

View full text Add to dashboard Cite

show abstract

“…Опубликованы данные о применении апремиласта и при других заболеваниях, в частности атопическом дерматите [35][36][37][38][39], синдроме Сафо (пустулезный артроостеит) [40], ревматоидном артрите [41], буллезном эпидермолизе [42,43], болезни Девержи [44][45][46], болезни Хейли -Хейли [47], акродерматите Аллопо [48], дискоидной красной волчанке [49], ихтиозе [50]. Таким образом, применение апремиласта является эффективным при среднетяжелом и тяжелом псориазе, в том числе при наличии коморбидных состояний, а также псориатическом артрите, особенно в тех случаях, когда предшествующая терапия не принесла желаемых результатов или отмечалась ее непереносимость.…”

Section: апремиласт: комбинированная терапия псориазаunclassified

Phosphodiesterase-4 inhibitor in the treatment of psoriasis and psoriatic arthritis

Olisova

Олисова²,

Svistunova

et al. 2019

Vestnik dermatologii i venerologii

View full text Add to dashboard Cite

Treatment of psoriasis and psoriatic arthritis, especially moderate and severe, represents difficulties. Recently, various methods of molecular medicine have been actively developed, however, targeted therapy deserves special attention, which consists of chemical agents that have specific target as a specific protein or enzyme. Targeted therapy is a promising direction in many branches of medicine, especially in dermatology.Despite the wide range of biological products, their use may be accompanied by an increased risk of infectious processes and malignant neoplasms, which makes the search for a new pharmacological solution in targeted therapy even more relevant.This review presents the possibilities and prospects for the therapeutic use of the phosphodiesterase-4 inhibitor from the group of small molecules — apremilast, primarily in the treatment of psoriasis and psoriatic arthritis.

show abstract

“…3 In the last decade, the advanced understanding of AD molecular pathways along with patient's and physician's demand for more effective therapies, led to the introduction of new therapeutic agents. 5 The underlying etiopathogenesis is multifaceted with a central role played by the relationship between impaired skin barrier and dysregulated immune response. 6 The first step in AD progress seems to be the altered skin barrier where environmental factors irrupt, leading to inflammatory response.…”

Section: Introductionmentioning

confidence: 99%

“…20 Currently, several pharmaceutical agents targeting TYK2, JAK1, JAK2, and JAK3 are being evaluated for the treatment of moderateto-severe AD. 4,5,20 This review will explore the current literature surrounding the use of baricitinib in AD.…”

Section: Introductionmentioning

confidence: 99%

<p>Profile of Baricitinib and Its Potential in the Treatment of Moderate to Severe Atopic Dermatitis: A Short Review on the Emerging Clinical Evidence</p>

Napolitano

Fabbrocini

Cinelli

et al. 2020

JAA

View full text Add to dashboard Cite

Atopic dermatitis (AD) is the most common chronic cutaneous inflammatory disease of childhood, affecting up to 25% of children; its prevalence in adulthood is currently unknown, since studies reported that AD may affect 0.3-14.3% of adult population. In the last decade, the advanced understanding of AD molecular pathways along with patient's and physician's demand for more effective therapies, led to the introduction of new therapeutic agents. Baricitinib is an oral JAK inhibitor highly selective for JAK1 and JAK2. Treatment with baricitinib improved the signs and symptoms of moderate-to-severe AD compared to placebo, but it will be essential to better understand the safety profile of this drug.

show abstract

Oral small molecules for the treatment of atopic dermatitis: a systematic review

Cited by 11 publications

References 49 publications

Interleukin‐13: Targeting an underestimated cytokine in atopic dermatitis

Interleukin‐13: Targeting an underestimated cytokine in atopic dermatitis

Phosphodiesterase-4 inhibitor in the treatment of psoriasis and psoriatic arthritis

<p>Profile of Baricitinib and Its Potential in the Treatment of Moderate to Severe Atopic Dermatitis: A Short Review on the Emerging Clinical Evidence</p>

Contact Info

Product

Resources

About